



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

#2

Rec'd PCT/PTO 24 SEP 2004

10/509365

Bescheinigung

Certificate

Attestation

REC'D 25 JUN 2003

WIPO

PCT

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02076448.6

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

Best Available Copy



Anmeldung Nr:
Application no.: 02076448.6
Demande no:

Anmeldetag:
Date of filing: 15.04.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

JANSSEN PHARMACEUTICA N.V.
Turnhoutsebaan 30
2340 Beerse
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted
with carbon-linked imidazoles or triazoles

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07D487/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE
DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES
OR TRIAZOLES

5

The present invention is concerned with novel tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles, the preparation thereof, pharmaceutical compositions comprising said novel compounds and the use of these compounds as a medicine as well as methods of treatment by administering said compounds. EPO - DG

10

15. 04. 2002

Oncogenes frequently encode protein components of signal transduction pathways which lead to stimulation of cell growth and mitogenesis. Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non-transformed cells. Mutation and/or overexpression of certain oncogenes is frequently associated with human cancer. A particular group of oncogenes is known as *ras* which have been identified in mammals, birds, insects, mollusks, plants, fungi and yeasts. The family of mammalian *ras* oncogenes consists of three major members ("isoforms"): *H-ras*, *K-ras* and *N-ras* oncogenes. These *ras* oncogenes code for highly related proteins generically known as p21^{ras}. Once attached to plasma membranes, the mutant or oncogenic forms of p21^{ras} will provide a signal for the transformation and uncontrolled growth of malignant tumor cells. To acquire this transforming potential, the precursor of the p21^{ras} oncoprotein must undergo an enzymatically catalyzed farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Therefore, inhibitors of the enzymes that catalyzes this modification, i.e. farnesyl transferase, will prevent the membrane attachment of p21^{ras} and block the aberrant growth of *ras*-transformed tumors. Hence, it is generally accepted in the art that farnesyl transferase inhibitors can be very useful as anticancer agents for tumors in which *ras* contributes to transformation. (102)

25
30

Since mutated oncogenic forms of *ras* are frequently found in many human cancers, most notably in more than 50 % of colon and pancreatic carcinomas (Kohl et al., *Science*, vol 260, 1834 - 1837, 1993), it has been suggested that farnesyl transferase inhibitors can be very useful against these types of cancer.

35


In EP-0,371,564 there are described (1*H*-azol-1-ylmethyl) substituted quinoline and quinolinone derivatives which suppress the plasma elimination of retinoic acids. Some of these compounds also have the ability to inhibit the formation of androgens from progestines and/or inhibit the action of the aromatase enzyme complex.

40

In WO 97/16443, WO 97/21701, WO 98/40383 and WO 98/49157, there are described 2-quinolone derivatives which exhibit farnesyl transferase inhibiting activity. WO 00/39082 describes a class of novel 1,2-annulated quinoline compounds, bearing a nitrogen- or carbon-linked imidazole, which show farnesyl protein transferase and geranylgeranyl transferase inhibiting activity. Other quinolinone compounds having farnesyl transferase inhibiting activity are described in WO 00/12498, WO 00/12499, WO 00/47574, WO 01/53289, WO 02/24682, WO 02/24683, WO 02/24686 and WO 02/24687.

Unexpectedly, it has been found that the present novel compounds, all having a phenyl substituent on the 4-position of the 2,3-annulated quinolinone moiety bearing a carbon-linked imidazole or triazole, show farnesyl protein transferase inhibiting activity. The present compounds can have advantage properties with regard to solubility and stability.

The present invention concerns compounds of formula (I):



or a pharmaceutically acceptable salt or N-oxide or stereochemically isomeric form thereof, wherein

r and s are each independently 0, 1, 2 or 3;

t is 0, 1, or 2;

each R¹ and R² are independently hydroxy, halo, cyano, nitro, C₁₋₆alkyl, (CR¹⁶R¹⁷)_p, -C₃₋₁₀cycloalkyl, cyanoC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, hydroxycarbonylC₁₋₆alkyl, R²⁰SC₁₋₆alkyl, trihalomethyl, arylC₁₋₆alkyl, Het¹C₁₋₆alkyl, -C₁₋₆alkyl-NR¹⁸R¹⁹, -C₁₋₆alkylNR¹⁸C₁₋₆alkyl-NR¹⁸R¹⁹, -C₁₋₆alkylNR¹⁸COC₁₋₆alkyl, -C₁₋₆alkylNR¹⁸COAr¹, -C₁₋₆alkylNR¹⁸COAr¹, C₁₋₆alkylsulphonylaminoC₁₋₆alkyl, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, -OC₁₋₆alkyl-NR¹⁸R¹⁹, trihalomethoxy,

arylC₁₋₆alkyloxy, Het¹C₁₋₆alkyloxy, C₂₋₆alkenyl, cyanoC₂₋₆alkenyl,
 -C₂₋₆alkenyl-NR¹⁸R¹⁹, hydroxycarbonylC₂₋₆alkenyl,
 C₁₋₆alkyloxycarbonylC₂₋₆alkenyl, C₂₋₆alkynyl, -CHO, C₁₋₆alkylcarbonyl,
 hydroxyC₁₋₆alkylcarbonyl, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl,
 5 -CONR¹⁸R¹⁹, -CONR¹⁸-C₁₋₆alkyl-NR¹⁸R¹⁹, -CONR¹⁸-C₁₋₆alkyl-Het¹,
 -CONR¹⁸-C₁₋₆alkyl-Ar¹, -CONR¹⁸-O-C₁₋₆alkyl, -CONR¹⁸-C₁₋₆alkenyl,
 -NR¹⁸R¹⁹, -OC(O)R²⁰, -CR²⁰=NR²¹, -CR²⁰=N-OR²¹, -NR²⁰C(O)NR¹⁸R¹⁹,
 -NR²⁰SO₂R²¹, -NR²⁰C(O)R²¹, -S(O)₀₋₂R²⁰, -SO₂NR²⁰R²¹, -C(NR²²R²³)=NR²⁴,
 or a group of formula

-CO-Z or -CO-NR^y-Z

in which R^y is hydrogen or C₁₋₄alkyl and Z is phenyl or a 5- or 6-
 membered heterocyclic ring containing one or more heteroatoms
 selected from oxygen, sulphur and nitrogen, the phenyl or heterocyclic
 ring being optionally substituted by one or two substituents each
 15 independently selected from halo, cyano, hydroxycarbonyl,
 aminocarbonyl, C₁₋₆alkylthio, hydroxy, -NR¹⁸R¹⁹,
 C₁₋₆alkylsulphonylamino, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkyloxy or
 phenyl; or

two R¹ and R² substituents adjacent to one another on the phenyl ring may
 20 independently form together a bivalent radical of formula

-O-CH₂-O- (a-1)

-O-CH₂-CH₂-O- (a-2)

-O-CH=CH- (a-3)

-O-CH₂-CH₂- (a-4) or

25 -O-CH₂-CH₂-CH₂- (a-5)

R¹⁶ and R¹⁷ are independently hydrogen or C₁₋₆ alkyl and are independently
 defined for each iteration of p in excess of 1;

30 R¹⁸ and R¹⁹ are independently hydrogen, C₁₋₆ alkyl or -(CR¹⁶R¹⁷)_p

-C₃₋₁₀cycloalkyl, or together with the adjacent nitrogen atom form a 5- or 6-
 membered heterocyclic ring optionally containing one, two or three further
 heteroatoms selected from oxygen, nitrogen or sulphur and optionally
 substituted by one or two substituents each independently selected from halo,
 35 hydroxy, cyano, nitro, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkyloxy, OCF₃,
 hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, aminocarbonyl,
 mono- or di-(C₁₋₆alkyl)aminocarbonyl, amino, mono- or di-(C₁₋₆alkyl)amino,
 C₁₋₆alkylsulfonylamino, oxime, or phenyl;

R^{20} and R^{21} are independently hydrogen, C_{1-6} alkyl,

$-(CR^{20}R^{21})_p-C_{3-10}$ cycloalkyl or aryl C_{1-6} alkyl;

R^{22} , R^{23} and R^{24} are independently hydrogen and C_{1-6} alkyl or $C(O)C_{1-6}$ alkyl;

- 5 R^3 is hydrogen, halo, cyano, C_{1-6} alkyl, $-(CR^{16}R^{17})_p-C_{3-10}$ cycloalkyl, halo C_{1-6} alkyl, cyano C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, aryl C_{1-6} alkyloxy C_{1-6} alkyl, C_{1-6} alkylthio C_{1-6} alkyl, hydroxycarbonyl C_{1-6} alkyl, C_{1-6} alkylcarbonyl C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl C_{1-6} alkyl, $-C_{1-6}$ alkyl- $NR^{18}R^{19}$, $-C_{1-6}$ alkyl- $CONR^{18}R^{19}$, aryl C_{1-6} alkyl, Het¹ C_{1-6} alkyl,
10 C_{2-6} alkenyl, $-C_{2-6}$ alkenyl $NR^{18}R^{19}$, C_{2-6} alkynyl, hydroxycarbonyl, C_{1-6} alkyloxycarbonyl, aryl, or Het¹; or a radical of formula

- | | | |
|----|--------------|----------|
| 15 | $-O-R^7$ | (b-1) |
| | $-S-R^7$ | (b-2) |
| | $-NR^8R^9$ | (b-3) or |
| | $-N=CR^7R^8$ | (b-4) |

- 20 wherein R^7 is hydrogen, C_{1-6} alkyl, $-(CR^{16}R^{17})_p-C_{3-10}$ cycloalkyl, aryl C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkylcarbonyl or $-C_{1-6}$ alkyl $C(O)OC_{1-6}$ alkyl $NR^{18}R^{19}$, or a radical of formula $-Alk-CR^{10}$ or $-Alk-NR^{11}R^{12}$;

- R^8 is hydrogen, C_{1-6} alkyl, $-(CR^{16}R^{17})_p-C_{3-10}$ cycloalkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

- 25 R^9 is hydrogen, hydroxy, C_{1-6} alkyl, $-(CR^{16}R^{17})_p-C_{3-10}$ cycloalkyl, C_{1-6} alkylcarbonyl C_{1-6} alkyl, aryl C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, C_{1-6} alkyloxy, a group of formula $-NR^{18}R^{19}$, C_{1-6} alkylcarbonylamino, C_{1-6} alkylcarbonyl, halo C_{1-6} alkylcarbonyl, aryl C_{1-6} alkylcarbonyl, arylcarbonyl, C_{1-6} alkyloxycarbonyl, trihalo C_{1-6} alkyloxycarbonyl,
30 C_{1-6} alkyloxy C_{1-6} alkylcarbonyl, aminocarbonyl, mono- or di(C_{1-6} alkyl)aminocarbonyl wherein the alkyl moiety may optionally be substituted by one or more substituents independently selected from aryl and C_{1-6} alkyloxycarbonyl substituents; aminocarbonylcarbonyl, mono- or di(C_{1-6} alkyl)amino C_{1-6} alkylcarbonyl, or a radical of formula
35 $-Alk-OR^{10}$ or $Alk-NR^{11}R^{12}$;

wherein Alk is C_{1-6} alkanediyl;


R^{10} is hydrogen, C_{1-6} alkyl, $-(CR^{16}R^{17})_p-C_{3-10}$ cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkylcarbonyl or hydroxy C_{1-6} alkyl;

R^{11} is hydrogen, C_{1-6} alkyl, $-(CR^{16}R^{17})_p-C_{3-10}$ cycloalkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

R^{12} is hydrogen, C_{1-6} alkyl, $-(CR^{16}R^{17})_p-C_{3-10}$ cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-6} alkylcarbonyl;

5

R^4 is a radical of formula



wherein R^{13} is hydrogen, halo or C_{1-6} alkyl;

R^{14} is hydrogen or C_{1-6} alkyl;

10

R^{15} is hydrogen or C_{1-6} alkyl;

R^5 is cyano, hydroxy, halo, C_{1-6} alkyl, $-(CR^{16}R^{17})_p-C_{3-10}$ cycloalkyl, C_{2-6} alkenyl,

C_{2-6} alkynyl, C_{1-6} alkyloxy, hydroxycarbonyl, C_{1-6} alkyloxycarbonyl, or a group of formula $-NR^{18}R^{19}$ or $-CONR^{18}R^{19}$;

15

R^6 is hydrogen, C_{1-6} alkyl, $-(CR^{16}R^{17})_p-C_{3-10}$ cycloalkyl, cyano C_{1-6} alkyl, $-C_{1-6}$ alkyl CO_2R^{20} , aminocarbonyl C_{1-6} alkyl or $-C_{1-6}$ alkyl $NR^{18}R^{19}$, $R^{20}SO_2$, $R^{20}SO_2C_{1-6}$ alkyl, $-C_{1-6}$ alkyl OR^{20} , $-C_{1-6}$ alkyl SR^{20} , $-C_{1-6}$ alkyl $CONR^{18}$ $-C_{1-6}$ alkyl $NR^{18}R^{19}$, $-C_{1-6}$ alkyl $CONR^{18}$ $-C_{1-6}$ alkyl Het^1 , $-C_{1-6}$ alkyl $CONR^{18}$ $-C_{1-6}$ alkyl Ar^1 , $-C_{1-6}$ alkyl $CONR^{18}$ $-Het^1$, $-C_{1-6}$ alkyl $CONR^{18}Ar^1$, $-C_{1-6}$ alkyl $CONR^{18}$ $-O$ $-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl $CONR^{18}$ $-C_{1-6}$ alkenyl, $-Alk$ $-Ar^1$ or $-Alk$ Het^1 ;

20

Ar^1 is phenyl, naphthyl or phenyl or naphthyl substituted by one to five substituents

25


each independently selected from halo, hydroxy, cyano, nitro, C_{1-6} alkyl,

halo C_{1-6} alkyl, $-alkylNR^{18}R^{19}$, C_{1-6} alkyloxy, OCF_3 , hydroxycarbonyl,

C_{1-6} alkyloxycarbonyl, $-CONR^{18}R^{19}$, $-NR^{18}R^{19}$, C_{1-6} alkylsulfonylamino, oxime or phenyl, or a bivalent substituent of formula



30



Het^1 is a mono- or bi-cyclic heterocyclic ring containing one or more

heteroatoms selected from oxygen, sulphur and nitrogen and optionally

substituted by one or two substituents each independently selected from halo,

hydroxy, cyano, nitro, C_{1-6} alkyl, halo C_{1-6} alkyl, $-alkylNR^{18}R^{19}$,

C_{1-6} alkyloxy, OCF_3 , hydroxycarbonyl, C_{1-6} alkyloxycarbonyl,
 $-CONR^{18}R^{19}$, $-NR^{18}R^{19}$, C_{1-6} alkylsulfonylamino, oxime or phenyl:

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro,
 5 bromo and iodo; C_{1-4} alkyl defines straight and branched chain saturated hydrocarbon
 radicals having from 1 to 4 carbon atoms such as, e.g. methyl, ethyl, propyl, butyl,
 1-methylethyl, 2-methylpropyl and the like; C_{1-6} alkyl includes C_{1-4} alkyl and the higher
 homologues thereof having 5 to 6 carbon atoms such as, for example, pentyl,
 2-methyl-butyl, hexyl, 2-methylpentyl and the like; C_{1-6} alkanediyl defines bivalent
 10 straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon
 atoms, such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butane-
 diyl, 1,5-pentanediy, 1,6-hexanediyl and the branched isomers thereof; halo C_{1-6} alkyl
 defines C_{1-6} alkyl containing one or more halo substituents for example trifluoromethyl;
 C_{2-6} alkenyl defines straight and branched chain hydrocarbon radicals containing one
 15 double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl,
 2-propenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, and the like;
 C_{2-6} alkynyl defines straight and branched chain hydrocarbon radicals containing one
 triple bond and having from 2 to 6 carbon atoms such as, for example, ethynyl,
 2-propynyl, 3-butyne-1,2-dienyl, 2-pentynyl, 3-pentynyl, 3-methyl-2-butyne-1,2-dienyl, and the like; the
 20 term "S(O)" refers to a sulfoxide and "S(O)₂" to a sulfone; aryl defines phenyl,
 naphthalenyl, phenyl substituted with one or more substituents each independently
 selected from halo, C_{1-6} alkyl, C_{1-6} alkyloxy, trifluoromethyl, cyano, or hydroxycarbonyl;
 or naphthalenyl substituted with one or more substituents each independently selected
 from halo, C_{1-6} alkyl, C_{1-6} alkyloxy, trifluoromethyl, cyano or hydroxycarbonyl;
 25 C_{3-10} cycloalkyl includes cyclic hydrocarbon groups having from 3 to 10 carbons, such
 as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl,
 cycloheptyl, cyclooctyl and the like.

Pharmaceutically acceptable addition salts encompass pharmaceutically acceptable acid
 30 addition salts and pharmaceutically acceptable base addition salts. The
 pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to
 comprise the therapeutically active non-toxic acid addition salt forms which the
 compounds of formula (I) are able to form. The compounds of formula (I) which have
 basic properties can be converted in their pharmaceutically acceptable acid addition
 35 salts by treating said base form with an appropriate acid. Appropriate acids comprise,
 for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic
 acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for
 example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic
 (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic,

ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-amino-salicylic, pamoic and the like acids.

The compounds of formula (I) which have acidic properties may be converted in their pharmaceutically acceptable base addition salts by treating said acid form with a
5 suitable organic or inorganic base. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, *N*-methyl-*D*-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

10 The term "acid or base addition salts" also comprises the hydrates and the solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

15 The term stereochemically isomeric forms of compounds of formula (I), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess. Unless otherwise
20 mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.

25 Some of the compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

30 Whenever used hereinafter, the term "compounds of formula (I)" is meant to include also the pharmaceutically acceptable acid addition salts and all stereoisomeric forms.

A group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply;

- 35 a) *r* and *s* are each independently 0, 1 or 2;
b) *t* is 0 or 1;
c) *R*¹ is halo, C₁₋₆alkyl, -(CR¹⁶R¹⁷)_p-C₃₋₁₀cycloalkyl, trihalomethyl, cyano

- trihalomethoxy, C₂₋₆alkenyl, hydroxycarbonylC₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, aminoC₁₋₆alkyloxy, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, -CONR¹⁸R¹⁹, or -CH=NOR²¹; or
- two R¹ substituents adjacent to one another on the phenyl ring may independently form together a bivalent radical of formula
- O-CH₂-O- (a-1), or
-O-CH₂-CH₂-O- (a-2);
- d) R² is halo, cyano, nitro, cyanoC₁₋₆alkyl, hydroxyC₁₋₆alkyl, -C₁₋₆alkyl NR¹⁸R¹⁹, Het¹C₁₋₆alkyl, cyanoC₂₋₆alkenyl, -NR¹⁸R¹⁹, CHO, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, -CO NR¹⁸R¹⁹; or
- two R² substituents adjacent to one another on the phenyl ring may independently form together a bivalent radical of formula
- O-CH₂-O- (a-1), or
-O-CH₂-CH₂-O- (a-2);
- e) R³ is hydrogen, halo, C₁₋₆alkyl, -(CR¹⁶R¹⁷)_p-C₃₋₁₀cycloalkyl, haloC₁₋₆alkyl, cyanoC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, -C₁₋₆alkyl NR¹⁸R¹⁹, Het¹C₁₋₆alkyl, -C₂₋₆alkenyl NR¹⁸R¹⁹, or -Het¹; or a group of formula
- O-R⁷ (b-1), or
-NR⁸R⁹ (b-3),
- wherein R⁷ is hydrogen, C₁₋₆alkyl, or -(CR¹⁶R¹⁷)_p-C₃₋₁₀cycloalkyl, or a group of formula -Alk-OR¹⁰ or -Alk-NR¹¹R¹²;
- R⁸ is hydrogen or C₁₋₆alkyl;
- R⁹ is hydrogen, hydroxy, C₁₋₆alkyl, -(CR¹⁶R¹⁷)_p-C₃₋₁₀cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkylcarbonyl, aminocarbonyl, or a radical of formula -Alk-OR¹⁰ or Alk-NR¹¹R¹²;
- wherein Alk is C₁₋₆alkanediyl;
- R¹⁰ is hydrogen, C₁₋₆alkyl or -(CR¹⁶R¹⁷)_p-C₃₋₁₀cycloalkyl;
- R¹¹ is hydrogen, C₁₋₆alkyl, or -(CR¹⁶R¹⁷)_p-C₃₋₁₀cycloalkyl;
- R¹² is hydrogen or C₁₋₆alkyl;
- f) R⁴ is a radical of formula (c-1) or (c-2) wherein
- R¹³ is hydrogen;
- R¹⁴ is C₁₋₆alkyl;
- R¹⁵ is C₁₋₆alkyl;
- g) R⁶ is hydrogen, C₁₋₆alkyl, -C₁₋₆alkylCO₂R²⁰, -C₁₋₆alkyl-C(O)NR¹⁸R¹⁹, -Alk-Ar¹, -AlkHet¹ or -(CR¹⁶R¹⁷)_p-C₃₋₁₀cycloalkyl,

- h) Het¹ is a 5- or 6-membered monocyclic heterocyclic ring containing one, two or three heteroatoms selected from oxygen, sulphur or nitrogen for example pyrrolidinyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, furyl, morpholinyl, piperazinyl, piperidinyl, thiophenyl, thiazolyl or oxazolyl, or a 9- or 10-membered bicyclic heterocyclic ring especially one in which a benzene ring is fused to a heterocyclic ring containing one, two or three heteroatoms selected from oxygen, sulphur or nitrogen for example indolyl, quinolinyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzothiazolyl or benzodioxolanyl.
- Another group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply;
- a) r is 0, 1 or 2;
 - b) s is 0 or 1;
 - c) t is 0;
 - d) R¹ is halo, cyano, C₁₋₆alkyl or two R¹ substituents ortho to one another on the phenyl ring may independently form together a bivalent radical of formula (a-1);
 - e) R² is halo, cyano, cyanoC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyl NR¹⁸R¹⁹, Het¹C₁₋₆alkyl, CHO, oxime, hydroxycarbonyl, or two R² substituents ortho to one another on the phenyl ring may independently form together a bivalent radical of formula (a-1);
 - f) R³ is hydrogen, Het¹ or a group of formula (b-1) or (b-3) wherein R⁷ is hydrogen or a group of formula -Alk-OR¹⁰. R⁸ is hydrogen; R⁹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, hydroxy, C₁₋₆alkyloxy or mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkylcarbonyl; Alk is C₁₋₆alkanediyl and R¹⁰ is hydrogen;
 - g) R⁴ is a radical of formula (c-1) or (c-2) wherein R¹³ is hydrogen; R¹⁴ is C₁₋₆alkyl; R¹⁵ C₁₋₆alkyl;
 - h) R⁶ is C₁₋₆alkyl, -(CR¹⁶R¹⁷)_p-C₃₋₁₀cycloalkyl, -C₁₋₆alkylCO₂R²⁰, aminocarbonylC₁₋₆alkyl, -Alk-Ar¹ or -AlkHet¹;
 - i) aryl is phenyl.

A particular group of compounds consists of those interesting compounds of formula (I) wherein one or more of the following restrictions apply;

- a) R^1 is 3-chloro or 3-methyl;
- b) R^2 is 4-chloro, 4-fluoro or 4-cyano;
- 5 c) R^6 is methyl or $-\text{CH}_2-\text{C}_{3-10}\text{cycloalkyl}$ most preferably $-\text{CH}_2\text{-cyclopropyl}$;
- d) R^4 is methyl.

Another particular group of compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply

- 10 a) r is 1, s is 1 and t is 0;
- b) R^1 is halo;
- c) R^2 is halo, $\text{C}_{1-6}\text{alkyl}$ or $\text{C}_{1-6}\text{alkyloxy}$;
- d) R^3 is a radical of formula (b-1) or (b-3) wherein R^7 is hydrogen, R^8 is hydrogen and R^9 is hydrogen;
- 15 e) R^4 is a radical of formula (c-1) wherein R^{13} is hydrogen and R^{14} is $\text{C}_{1-6}\text{alkyl}$;
- f) R^6 is hydrogen.

A further particular group of compounds consists of those compounds of formula (I) wherein R^1 is halo, $\text{C}_{1-6}\text{alkyl}$ or forms a bivalent radical of formula (a-1); R^2 is halo, cyano, $\text{C}_{1-6}\text{alkyl}$, or $\text{C}_{1-6}\text{alkyloxy}$; R^3 is hydrogen or a radical of formula (b-1) or (b-3) wherein R^7 is hydrogen or $-\text{Alk}-\text{OR}^{10}$, R^8 is hydrogen, R^9 is hydrogen or $\text{C}_{1-6}\text{alkylcarbonyl}$ and R^{10} is hydrogen; R^4 is a radical of formula (c-1) or (c-2) wherein R^{13} is hydrogen and R^{14} and R^{15} are $\text{C}_{1-6}\text{alkyl}$; and R^6 is hydrogen, $\text{C}_{1-6}\text{alkyl}$, $-\text{CH}_2-\text{C}_{3-10}\text{cycloalkyl}$ or $-\text{C}_{1-6}\text{alkylAr}^1$.

25

Preferred compounds are those compounds of formula (I) wherein R^1 is halo, $\text{C}_{1-6}\text{alkyl}$ or forms a bivalent radical of formula (a-1); R^2 is halo, cyano, $\text{C}_{1-6}\text{alkyl}$, or $\text{C}_{1-6}\text{alkyloxy}$; R^3 is hydrogen or a radical of formula (b-1) or (b-3) wherein R^7 is hydrogen or $-\text{Alk}-\text{OR}^{10}$, R^8 is hydrogen, R^9 is hydrogen or $\text{C}_{1-6}\text{alkylcarbonyl}$ and R^{10} is hydrogen; R^4 is a radical of formula (c-1) wherein R^{13} is hydrogen and R^{14} is $\text{C}_{1-6}\text{alkyl}$; and R^6 is hydrogen, $\text{C}_{1-6}\text{alkyl}$, $-\text{CH}_2-\text{C}_{3-10}\text{cycloalkyl}$ or $-\text{C}_{1-6}\text{alkylAr}^1$.

30

More preferred compounds are those compounds of formula (I) wherein R^1 is halo; R^2 is halo, $\text{C}_{1-6}\text{alkyl}$ or $\text{C}_{1-6}\text{alkyloxy}$; R^3 is a radical of formula (b-1) or (b-3) wherein R^7 is hydrogen, R^8 is hydrogen and R^9 is hydrogen; R^4 is a radical of formula (c-1) wherein R^{13} is hydrogen and R^{14} is methyl; and R^6 is hydrogen.


35

Most preferred compounds are

- 9-(3-chlorophenyl)- α -(4-fluorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)-
tetrazolo[5,1-*b*]quinazoline-7-methanol
9-(3-chlorophenyl)-4,9-dihydro- α -(4-methoxyphenyl)- α -(1-methyl-1*H*-imidazol-5-yl)-
tetrazolo[5,1-*b*]quinazoline-7-methanol
5 9-(3-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- α -(4-methylphenyl)-
tetrazolo[5,1-*b*]quinazoline-7-methanamine (A)
9-(3-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- α -(4-methylphenyl)-
tetrazolo[5,1-*b*]quinazoline-7-methanamine (B)
9-(3-chlorophenyl)- α -(4-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)-
10 tetrazolo[5,1-*b*]quinazoline-7-methanol.


The compounds of formula (I) and their pharmaceutically acceptable salts and
N-oxides and stereochemically isomeric forms thereof may be prepared, for example,
15 by the following processes:

- a) the compounds of formula (I) wherein R^4 represents a radical of formula (c-1), R^3 is
hydroxy and R^{14} is C_{1-6} alkyl, said compounds being referred to as compounds of
formula (I-a-1) may be prepared by reacting an intermediate ketone of formula (II) with
20 an intermediate of formula (III-a-1) wherein R^{14} is C_{1-6} alkyl. Said reaction requires the
presence of a suitable strong base, such as, for example, butyl lithium in an appropriate
solvent, such as, for example, tetrahydrofuran, and the presence of an appropriate silane
derivative, such as, for example, triethylchlorosilane. During the work-up procedure an
intermediate silane derivative is hydrolyzed. Other procedures with protective groups.
25 analogous to silane derivatives can also be applied.




- b) the compounds of formula (I), wherein R^4 is a radical of formula (c-1), R^3 is hydroxy
and R^{14} is hydrogen, said compounds being referred to as compounds of formula (I-b-
1) may be prepared by reacting an intermediate ketone of formula (II) with an
30 intermediate of formula (III-b-1) wherein P is an optional protective group such as, for
example, a sulfonyl group, e.g. a dimethylamino sulfonyl group, which can be removed


after the addition reaction. Said reaction requires the presence of a suitable strong base, such as, for example, butyl lithium in an appropriate solvent, such as tetrahydrofuran and the presence of an appropriate silanederivative, such as, for example, triethylchlorosilane. During the work-up procedure an intermediate silane derivative is hydrolyzed. Other procedures with protective groups analogues to silanederivatives can also be applied.



c) compounds of formula (I), wherein R^4 is a radical of formula (c-2), R^{15} is C_{1-6} alkyl and R^3 is hydroxy, said compounds being referred to as compounds of formula (I-a-2), may be prepared by reacting an intermediate ketone of formula (II) with an intermediate triazole reagent of formula (III-a-2) wherein R^{25} is hydrogen or C_{1-6} alkyl, to form intermediates of formula (IVa-2) and subsequently removing the 3-mercapto or the 3- C_{1-6} alkylmercapto group. More in particular, the compounds of formula (I-a-2) may be prepared by reacting the compound of formula (II) with the triazole reagent (III-a-2), preferably in a reaction-inert solvent such as tetrahydrofuran, in the presence of a strong base such as butyl lithium at a temperature ranging from -78°C to room temperature. Removal of the 3-mercapto group is conveniently effected with sodium nitrite, for example in THF/ H_2O in the presence of nitric acid. Removal of, for example, the 3-methylmercapto group is conveniently effected with Raney Nickel in ethanol or acetone.



d) Compounds of formula (I), wherein R^4 is a radical of formula (c-2), R^{15} is hydrogen
 5 and R^3 is hydroxy, said compounds being referred to as compounds of formula (I-b-2),
 may be prepared by reacting an intermediate ketone of formula (II) with an
 intermediate triazole reagent of formula (III-b-2) wherein P is an optional protective
 group such as, for example, a sulfonyl group, e.g. a dimethylamino sulfonyl group,
 which can be removed after the addition reaction. Said reaction requires the presence of
 10 a suitable strong base, such as, for example, butyl lithium in an appropriate
 silanederivative, such as, for example, triethylchlorosilane. During the work-up
 procedure an intermediate silane derivative is hydrolyzed. Other procedures with
 protective groups analogues to silanederivatives can also be applied.



15


Compounds of formula (I-a-1), (I-b-1), (I-a-2) and (I-b-2) can optionally be the subject
 of one or more of the following conversions in any desired order:

- (i) converting a compound of formula (I) into a different compound of formula (I);
- 20 (ii) converting a compound of formula (I) into its corresponding pharmaceutically
 acceptable salt or N-oxide thereof;
- (iii) converting a pharmaceutically acceptable salt or N-oxide of a compound of
 formula (I) into the parent compound of formula (I);


(iv) preparing a stereochemical isomeric form of a compound of formula (I) or a pharmaceutically acceptable salt or N-oxide thereof.

5 Examples of the conversion of one compound of formula (I) into a different compound of formula (I) include the following reactions:

a) Compounds of formula (I-c) wherein R^3 is hydroxy, can be converted into compounds of formula (I-d), defined as a compound of formula (I) wherein R^3 is hydrogen, by submitting the compounds of formula (I-c) to appropriate reducing conditions, such as, e.g. stirring in acetic acid in the presence of formamide, or
10 treatment with sodium borohydride/ trifluoroacetic acid.



b) Compounds of formula (I-c) can be converted to compounds of formula (I-e) wherein R^3 is halo, by reacting the compounds of formula (I-c) with a suitable
15 halogenating agent, such as, e.g. thionyl chloride or phosphorus tribromide. Successively, the compounds of formula (I-e) can be treated with a reagent of formula $H-NR^8R^9$ in a reaction-inert solvent, thereby yielding compounds of formula (I-f).




c) Alternatively compounds of formula (I-c) can be converted into compounds of formula (I-f), for example, by treatment with $SOCl_2$, and then $NH_3/iPrOH$, e.g. in a
20 tetrahydrofuran solvent, or by treatment with acetic acid ammonium salt at a temperature ranging from 120 to 180°C, or by treatment with sulfamide at a temperature ranging from 120 to 180°C.

d) The compounds of formula (I) may also be converted into each other via art-known reactions or functional group transformations. A number of such transformations are already described hereinabove. Other examples are hydrolysis of carboxylic esters to the corresponding carboxylic acid or alcohol; hydrolysis of amides to the corresponding carboxylic acids or amines; hydrolysis of nitriles to the corresponding amides; amino groups on imidazole or phenyl may be replaced by a hydrogen by art-known diazotation reactions and subsequent replacement of the diazo-group by hydrogen; alcohols may be converted into esters and ethers; primary amines may be converted into secondary or tertiary amines; double bonds may be hydrogenated to the corresponding single bond; an iodo radical on a phenyl group may be converted in to an ester group by carbon monoxide insertion in the presence of a suitable palladium catalyst.

The intermediates and starting materials used in the above-described processes may be prepared in conventional manner using procedures known in the art for example as described in the above-mentioned patent specifications WO 97/16443, WO 97/21701, WO 98/40383, WO 98/49157 and WO 00/39082.

For example intermediates of formula (V) can be prepared by procedures described in International Patent Specification No. WO 00/39082, from page 9 to page 15, or by processes analogues thereto. Intermediates of formula (V) can be further converted in compounds of formula (I) wherein R^6 is hydrogen said compounds being referred to as compounds of formula (I-g) by heating at 120 °C in an appropriate solvent such as toluene.



The compounds of formula (I) and some of the intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration.

The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a
5 suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the
10 corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

15 The compounds of formula (I), the pharmaceutically acceptable acid addition salts and stereoisomeric forms thereof have valuable pharmacological properties in that they have a potent farnesyl protein transferase (FPTase) inhibitory effect.

20 This invention provides a method for inhibiting the abnormal growth of cells, including transformed cells, by administering an effective amount of a compound of the invention. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g. loss of contact inhibition). This includes the abnormal growth of : (1) tumor cells (tumors) expressing an activated *ras* oncogene; (2) tumor
25 cells in which the *ras* protein is activated as a result of oncogenic mutation of another gene; (3) benign and malignant cells of other proliferative diseases in which aberrant *ras* activation occurs. Furthermore, it has been suggested in literature that *ras* oncogenes not only contribute to the growth of tumors *in vivo* by a direct effect on tumor cell growth but also indirectly, *i.e.* by facilitating tumor-induced angiogenesis
30 (Rak. J. et al, *Cancer Research*, 55, 4575-4580, 1995). Hence, pharmacologically targeting mutant *ras* oncogenes could conceivably suppress solid tumor growth *in vivo*, in part, by inhibiting tumor-induced angiogenesis.

35 This invention also provides a method for inhibiting tumor growth by administering an effective amount of a compound of the present invention, to a subject, e.g. a mammal (and more particularly a human) in need of such treatment. In particular, this invention provides a method for inhibiting the growth of tumors expressing an activated *ras* oncogene by the administration of an effective amount of the compounds of the present invention. Examples of tumors which may be inhibited, but are not limited to, are:

cancer (e.g. adenocarcinoma and including non-small cell lung cancer), pancreatic cancers (e.g. pancreatic carcinoma such as, for example exocrine pancreatic carcinoma), colon cancers (e.g. colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), prostate cancer including the advanced disease, hematopoietic tumors of lymphoid lineage (e.g. acute lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), tumors of mesenchymal origin (e.g. fibrosarcomas and rhabdomyosarcomas), melanomas, teratocarcinomas, neuroblastomas, gliomas, benign tumor of the skin (e.g. keratoacanthomas), breast carcinoma (e.g. advanced breast cancer), kidney carcinoma, ovary carcinoma, bladder carcinoma and epidermal carcinoma.

This invention may also provide a method for inhibiting proliferative diseases, both benign and malignant, wherein *ras* proteins are aberrantly activated as a result of oncogenic mutation in genes. With said inhibition being accomplished by the administration of an effective amount of the compounds described herein, to a subject in need of such a treatment. For example, the benign proliferative disorder neurofibromatosis, or tumors in which *ras* is activated due to mutation or overexpression of tyrosine kinase oncogenes, may be inhibited by the compounds of this invention.

The compound according to the invention can be used for other therapeutic purposes, for example:

- a) the sensitisation of tumors to radiotherapy by administering the compound according to the invention before, during or after irradiation of the tumor for treating cancer, for example as described in WO 00/01411;
- b) treating athropathies such as rheumatoid arthritis, osteoarthritis, juvenile arthritis, gout, polyarthritis, psoriatic arthritis, ankylosing spondylitis and systemic lupus erythematosus, for example as described in WO 00/01386;
- c) inhibiting smooth muscle cell proliferation including vascular proliferative disorders, atherosclerosis and restenosis, for example as described in WO 98/55124;
- d) treating inflammatory conditions such as ulcerative colitis, Crohn's disease, allergic rhinitis, graft vs host disease, conjunctivitis, asthma, ARDS, Behcets disease, transplant rejection, uticaria, allergic dermatitis, alopecia areata, scleroderma, exanthem, eczema, dermatomyositis, acne, diabetes, systemic lupus erythematosus, Kawasaki's disease, multiple sclerosis, emphysema, cystic fibrosis and chronic bronchitis;
- e) treating endometriosis, uterine fibroids, dysfunctional uterine bleeding and endometrial hyperplasia;

- f) treating ocular vascularisation including vasculopathy affecting retinal and choroidal vessels;
- g) treating pathologies resulting from heterotrimeric G protein membrane fixation including diseases related to following biological functions or disorders; smell, taste, light, perception, neurotransmission, neurodegeneration, endocrine and exocrine gland functioning, autocrine and paracrine regulation, blood pressure, embryogenesis, viral infections, immunological functions, diabetes, obesity;
- h) inhibiting viral morphogenesis for example by inhibiting the prenylation or the post-prenylation reactions of a viral protein such as the large delta antigen of hepatitis D virus; and the treatment of HIV infections;
- i) treating polycystic kidney disease;
- j) suppressing induction of inducible nitric oxide including nitric oxide or cytokine mediated disorders, septic shock, inhibiting apoptosis and inhibiting nitric oxide cytotoxicity;
- k) treating malaria.

The compounds of present invention may be particularly useful for the treatment of proliferative diseases, both benign and malignant, wherein the *K-ras* B isoform is activated as a result of oncogenic mutation.

Hence, the present invention discloses the compounds of formula (I) for use as a medicine as well as the use of these compounds of formula (I) for the manufacture of a medicament for treating one or more of the above mentioned conditions.

For the treatment of the above conditions, the compound of the invention may be advantageously employed in combination with one or more other medicinal agents such as anti-cancer agents for example selected from platinum coordination compounds for example cisplatin or carboplatin, taxane compounds for example paclitaxel or docetaxel, camptothecin compounds for example irinotecan or topotecan, anti-tumor vinca alkaloids for example vinblastine, vincristine or vinorelbine, anti-tumor nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine, nitrogen mustard or nitrosourea alkylating agents for example cyclophosphamide, chlorambucil, carmustine or lomustine, anti-tumor anthracycline derivatives for example daunorubicin, doxorubicin or idarubicin; HER2 antibodies for example trastuzumab; and anti-tumor podophyllotoxin derivatives for example etoposide or teniposide; and antiestrogen agents including estrogen receptor antagonists or selective estrogen receptor modulators preferably tamoxifen, or alternatively toremifene, droloxifene, faslodex and raloxifene, or aromatase inhibitors such as exemestane, anastrozole, letrozole and vorozole.

For the treatment of cancer the compounds according to the present invention can be administered to a patient as described above, in conjunction with irradiation. Such treatment may be especially beneficial, as farnesyl transferase inhibitors can act as
5 radiosensitisers, for example as described in International Patent Specification WO 00/01411, enhancing the therapeutic effect of such irradiation.

Irradiation means ionizing radiation and in particular gamma radiation, especially that emitted by linear accelerators or by radionuclides that are in common use today. The
10 irradiation of the tumor by radionuclides can be external or internal.

Preferably, the administration of the farnesyl transferase inhibitor commences up to one month, in particular up to 10 days or a week, before the irradiation of the tumor. Additionally, it is advantageous to fractionate the irradiation of the tumor and maintain
15 the administration of the farnesyl transferase inhibitor in the interval between the first and the last irradiation session.

The amount of farnesyl protein transferase inhibitor, the dose of irradiation and the intermittence of the irradiation doses will depend on a series of parameters such as the
20 type of tumor, its location, the patient's reaction to chemo- or radiotherapy and ultimately is for the physician and radiologists to determine in each individual case.

The present invention also concerns a method of cancer therapy for a host harboring a tumor comprising the steps of

- 25
- administering a radiation-sensitizing effective amount of a farnesyl protein transferase inhibitor according to the invention before, during or after
 - administering radiation to said host in the proximity to the tumor.

In view of their useful pharmacological properties, the subject compounds may be
30 formulated into various pharmaceutical forms for administration purposes.

To prepare the pharmaceutical compositions of this invention, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which
35 carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water,

glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets.

5

Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, as a transdermal patch, as a spot-on or as an ointment.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient, calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

Those skilled in the art could easily determine the effective amount from the test results presented hereinafter. In general it is contemplated that a therapeutically effective amount would be from 0.001 mg/kg to 100 mg/kg body weight, and in particular from 0.5 mg/kg to 100 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.5 to 500 mg. and in particular 10 mg to 500 mg of active ingredient per unit dosage form.

Experimental part

The following examples are provided for purposes of illustration.

- 5 Hereinafter "THF" means tetrahydrofuran, "EtOAc" means ethyl acetate, and "BuLi" means n-butyl lithium, "DIPE" means diisopropyl ether, "DCM" means dichloromethane "DMSO" means dimethylsulfoxide, "DMF" means N,N-dimethylformamide, "BTEAC" means benzyltriethylammonium salt and 'mp' means melting point.

10

A. Preparation of the intermediates

Example A1

- 15 a) nBuLi 1.6M in hexane (0.112 mol) was added dropwise at -70°C under N₂ flow to a mixture of 5-bromo-3-(3-chlorophenyl)-2,1-benzisoxazole (0.097 mol) in THF (300ml). The mixture was stirred at -70°C for 15 min. A mixture of 4-fluorobenzaldehyde (0.112 mol) in THF (100ml) was added dropwise. The mixture was stirred at -70°C for 30 min, then hydrolyzed and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated till dryness. The residue was taken up in diethyl ether and DIPE. The precipitate was filtered off, washed and dried, yielding 9.2g (26.8%) of 3-(3-chlorophenyl)-α-(4-fluorophenyl)-2,1-benzisoxazole-5-methanol (intermediate 1), mp. 171°C.
- 20 b) A mixture of intermediate 1 (0.0514 mol) and MnO₂ (18g) in 1,4-dioxane (200ml) was stirred at 80°C for 3 hours, then cooled to room temperature and filtered over celite. The solvent was evaporated till dryness. The product was used without further purification, yielding (quant.) of [3-(3-chlorophenyl)-2,1-benzisoxazol-5-yl](4-fluorophenyl)-methanone (intermediate 2), mp. 165°C.
- 25 c) A mixture of intermediate 2 (0.0514 mol) in THF (180ml) was cooled on an ice bath. TiCl₃ 15% in water (180ml) was added dropwise slowly. The mixture was stirred at room temperature overnight, then poured out into ice water and extracted with DCM. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated till dryness, yielding 18.2g (100%) of [2-amino-5-(4-fluorobenzoyl)phenyl](3-chlorophenyl)-methanone (intermediate 3).
- 30 d) Trichloro-acetylchloride (0.0848 mol) was added dropwise at 5°C to a mixture of intermediate 3 (0.0707 mol) in DCM (250ml) under N₂ flow. The mixture was stirred at 5°C for 30 minutes. Triethylamine (0.0848 mol) was added dropwise at 5°C. The mixture was stirred at 5°C for 1 hour, then at room temperature for 2 hours and poured out into ice water. DCM was added. The mixture was extracted with DCM. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The
- 35

residue was crystallized from diethyl ether/DIPE. The precipitate was filtered off and dried, yielding 33.7g (95%) of 2,2,2-trichloro-*N*-[2-(3-chlorobenzoyl)-4-(4-fluorobenzoyl)phenyl]- acetamide (intermediate 4) .

5 e) Acetic acid, ammonium salt (0.135 mol) was added at room temperature to a mixture of intermediate 4 (0.0675 mol) in DMSO (300ml). The mixture was stirred at 60°C for 4 hours, then brought to room temperature and poured out into water. The precipitate was filtered, washed with water, taken up in warm CH₃CN, filtered, washed again with CH₃CN, then with diethyl ether and dried under a vacuo, yielding 18.5g (72%) of intermediate 5. The mother layer was purified by column chromatography over silica
10 gel (eluent: CH₂Cl₂/CH₃OH:NH₄OH 95/5/0.1; 15-40μm). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-propanone/diethyl ether. The precipitate was filtered off and dried, yielding 1.8g (7%) of 4-(3-chlorophenyl)-6-(4-fluorobenzoyl)- 2(1*H*)-quinazolinone (intermediate 5), mp. 226°C.

15 f) Intermediate 5 (0.0528 mol) was added in phosphoryl chloride (200ml) at room temperature. The mixture was stirred at 100°C for 3 hours and cooled to room temperature. The solvent was evaporated. The residue was taken up in DCM. The solvent was evaporated till dryness. The residue was taken up in DCM, poured out into ice water, neutralized with K₂CO₃ solid and extracted with DCM. The organic layer
20 was washed with water, separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was crystallized from 2-propanone. The precipitate was filtered off and dried, yielding 8.5g (40%) of intermediate 6. The mother layer was evaporated. The residue was purified by column chromatography over silica gel (eluent: toluene/EtOAc 95/5; 15-35μm). The pure fractions were collected and the
25 solvent was evaporated. A part (0.5g) of the residue (8.9g, 42%) was crystallized from 2-propanone. The precipitate was filtered off and dried, yielding 0.3g of [2-chloro-4-(3-chlorophenyl)-6-quinazolinyl](4-fluorophenyl)- methanone (intermediate 6), mp. 138°C.

30 g) BuLi 1.6M in hexane (46.5ml, 0.0744 mol) was added dropwise at -70°C to a mixture of 1-methyl-1*H*-imidazole (0.0744 mol) in THF (70ml) under N₂ flow. Chlorotriethyl-silane (0.0765 mol) was added dropwise at -70°C. The mixture was stirred at -70°C for 15 minutes. BuLi 1.6M in hexane (41ml, 0.0659 mol) was added dropwise at -70°C. The mixture was stirred at -70°C for 15 minutes. A solution of intermediate 6 (0.0425 mol) in THF (150ml) was added dropwise at -70°C. The
35 mixture was stirred at -70°C for 1 hour and poured out into water. EtOAc was added. The mixture was extracted with EtOAc. The organic layer was washed twice with water, separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent:

CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.5; 15-35 μ m). The pure fractions were collected and the solvent was evaporated. Part (0.5g) of the residue (14.6g, 72%) was crystallized from 2-propanone/CH₃CN. The precipitate was filtered off and dried under a vacuo, yielding 0.17g of 2-chloro-4-(3-chlorophenyl)- α -(4-fluorophenyl)- α -(1-methyl-1*H*-imidazol-5-yl)-6-quinazolinemethanol (intermediate 7), mp. 212°C.

- 5 h) A mixture of intermediate 7 (0.0125 mol) and NaN₃ (0.038 mol) in DMF (60ml) was stirred at 90°C for 2 hours, then brought to room temperature, poured out into ice water and stirred. The precipitate was filtered, washed with water, taken up in DCM, filtered, washed with diethyl ether and dried under a vacuo, yielding 3.5g (58%) of intermediate
- 10 8. The filtrate was extracted with DCM. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.1; 15-40 μ m). The pure fractions were collected and the solvent was evaporated. The residue (0.9g, 15%) was crystallized from 2-propanone. The precipitate was filtered off and dried,
- 15 yielding 0.7g (12%) of 5-(3-chlorophenyl)- α -(4-fluorophenyl)- α -(1-methyl-1*H*-imidazol-5-yl)-tetrazolo[1,5-*a*]quinazoline-7-methanol (intermediate 8), mp. 200°C.
- i) NaBH₄ (0.001 mol) was added portionwise at room temperature to a mixture of intermediate 8 (0.001 mol) in methanol (5ml). The mixture was stirred at room
- 20 temperature for 2 hours and poured out into ice water. DCM was added. The organic layer was washed with water, separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was crystallized from 2-propanone. The precipitate was filtered off and dried in a vacuo. The residue (0.35g, 70%) was crystallized from ethanol. The precipitate was filtered off and dried in a vacuo, yielding 0.105g (21%) of
- 25 5-(3-chlorophenyl)- α -(4-fluorophenyl)-4,5-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)-tetrazolo[1,5-*a*]quinazoline-7-methanol (intermediate 9), mp. 230°C.

Example A2

- a) 5-bromo-3-(3-chlorophenyl)-2,1-benzisoxazole (0.13 m) was added at -70°C to THF (300ml) under N₂ flow. A solution of BuLi (0.143 mol) was added dropwise. The
- 30 mixture was stirred at -70°C for 10 minutes. A solution of *N*,4-dimethoxy-*N*-methylbenzamide (0.117 mol) in THF (100ml) was added dropwise at -70°C. The mixture was stirred at -70°C for 1 hour, poured out on ice/EtOAc and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and
- 35 dried under a vacuo, yielding 19.5g (41%) of [3-(3-chlorophenyl)-2,1-benzisoxazol-5-yl](4-methoxyphenyl)-methanone (intermediate 10).
- b) Intermediate 10 (0.0536 mol) was added at room temperature to THF (200ml). TiCl₃ 15% in water (120ml) was added dropwise at room temperature. The mixture was

stirred at room temperature for 3 hours, poured out into ice water and extracted with DCM. The organic layer was separated, washed with K_2CO_3 10% then with water, dried ($MgSO_4$), filtered and the solvent was evaporated, yielding 20.5g (quantitative) of [2-amino-5(4-methoxybenzoyl)phenyl](3-chlorophenyl)-methanone (intermediate 11).

5 c) A mixture of intermediate 11 (0.0536 mol) in DCM (200ml) was cooled to 5°C under N_2 flow. A solution of trichloro-acetylchloride (0.0643 mol) was added dropwise at 5°C. The mixture was stirred at 5°C for 30 minutes. A solution of triethylamine (0.0643 mol) was added dropwise at 5°C. The mixture was stirred at 5°C for 1 hour then at room temperature for 2 hours, poured out into ice water and extracted with
10 DCM. The organic layer was separated, washed with water, dried ($MgSO_4$), filtered and the solvent was evaporated, yielding 27.4g (quantitative) of 2,2,2-trichloro-N-[2-(3-chlorobenzoyl)-4-(4-methoxybenzoyl)phenyl]-acetamide (intermediate 12).

d) Acetic acid, ammonium salt (0.107 mol) was added at room temperature to a mixture of intermediate 12 (0.0536 mol) in DMSO (250ml). The mixture was stirred at 60°C for
15 4 hours then brought to room temperature, poured out into ice water and stirred. The precipitate was filtered, washed with water and taken up in warm CH_3CN . The precipitate was filtered, washed with diethyl ether and dried under a vacuo, yielding 16.2g (77%) of intermediate 13. The mother layer was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH_2Cl_2/CH_3CN ,
20 95/5/0.1; 15-40 μ m). The pure fractions were collected and the solvent was evaporated. The residue (1.2g, 6%) was crystallized from 2-propanone. The precipitate was filtered off and dried, yielding 0.9g (4%) of 4-(3-chlorophenyl)-6-(4-methoxybenzoyl)-2(1H)-quinazolinone (intermediate 13), mp. 248°C.

e) Intermediate 13 (0.0432 mol) was added at room temperature to phosphoryl chloride
25 (150ml). The mixture was stirred at 100°C for 3 hours then brought to room temperature. The solvent was evaporated till dryness. The residue was taken up in DCM. The solvent was evaporated. The residue was taken up in DCM. The mixture was poured out into ice water, neutralized with K_2CO_3 solid and extracted with DCM. The organic layer was separated, washed with water, dried ($MgSO_4$), filtered and the
30 solvent was evaporated. The residue was crystallized from CH_3CN . The precipitate was filtered off and dried under a vacuo, yielding 15.5g (87%) of intermediate 14. The mother layer was purified by column chromatography over silica gel (eluent: toluene/EtOAc; 93/7; 15-40 μ m). The pure fractions were collected and the solvent was evaporated. The residue (0.7g, 4%) was crystallized from 2-propanone. The precipitate
35 was filtered off and dried under a vacuo, yielding 0.5g (3%) of [2-chloro-4-(3-chlorophenyl)-6-quinazolinyl](4-methoxyphenyl)-methanone (intermediate 14), mp. 175°C.

- f) nBuLi (0.0665 mol) was added dropwise at -70°C to a solution of 1-methyl-1*H*-imidazole (0.0665 mol) in THF (60ml) under N₂ flow. The mixture was stirred for 15 minutes. Chlorotriethyl-silane (0.0684 mol) was added dropwise. The mixture was stirred for 15 minutes. nBuli (0.059 mol) was added dropwise. The mixture was stirred for 15 minutes. A solution of intermediate 14 (0.038 mol) in THF (150ml) was added at -70°C. The mixture was stirred at -70°C for 1 hour and poured out into water. EtOAc was added. The mixture was extracted with EtOAc. The organic layer was washed with water, separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.2 ; 15-35μm). The pure fractions were collected and the solvent was evaporated, yielding 11g (59%) of 2-chloro-4-(3-chlorophenyl)-α-(4-methoxyphenyl)-α-(1-methyl-1*H*-imidazol-5-yl)-6-quinazolinemethanol (intermediate 15).
- g) A mixture of intermediate 15 (0.0224 mol) and NaN₃ (0.067 mol) in DMF (120ml) was stirred at 90°C for 2 hours, brought to room temperature, poured out into ice water and stirred. The precipitate was filtered, washed with water and taken up in DCM. The organic layer was washed with water, separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: toluene/iPrOH/NH₄OH 90/10/1 ; 15-40μm). The pure fractions were collected and the solvent was evaporated, yielding 9g (80%) of 5-(3-chlorophenyl)-α-(4-methoxyphenyl)-α-(1-methyl-1*H*-imidazol-5-yl)-tetrazolo[1,5-*a*]quinazoline-7-methanol (intermediate 16), mp 200°C.
- h) NaBH₄ (0.003 mol) was added portionwise at room temperature to a mixture of intermediate 16 (0.003 mol) in methanol (15ml). The mixture was stirred at room temperature for 2 hours and poured out into ice water. DCM was added. The mixture was extracted with DCM. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (1.3g, 86%) was crystallized from 2-propanone/diethyl ether. The precipitate was filtered off and dried, yielding 1g (67%) of 5-(3-chlorophenyl)-4,5-dihydro-α-(4-methoxyphenyl)-α-(1-methyl-1*H*-imidazol-5-yl)-tetrazolo[1,5-*a*]quinazoline-7-methanol (intermediate 17) , mp. 220°C.

Example A3

- a) nBuLi 1.6 M in hexane (0.112 mol) was added dropwise at -70°C under N₂ flow to a mixture of 5-bromo-3-(3-chlorophenyl)-2,1-benzisoxazole (0.097 mol) in THF (300ml). The mixture was stirred at -70°C for 15 min. A mixture of 4-methyl-benzaldehyde (0.112 mol) in THF (100ml) was added dropwise. The mixture was stirred at -70°C for 30 min, then hydrolized and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated till

dryness. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ 96/4; 20-45 μm). The pure fractions were collected and the solvent was evaporated, yielding 13g (38.3%) of 3-(3-chlorophenyl)- α -(4-methylphenyl)-2,1-benzisoxazole-5-methanol (intermediate 18).

- 5 b) A mixture of intermediate 18 (0.071 mol) and MnO_2 (0.287 mol) in 1,4-dioxane (250ml) was stirred at 80°C for 2 hours, then cooled to room temperature, filtered over celite and washed with DCM. The solvent was evaporated till dryness, yielding 24.7g (100%) of [3-(3-chlorophenyl)-2,1-benzisoxazol-5-yl](4-methylphenyl)-methanone (intermediate 19).
- 10 c) A mixture of intermediate 19 (0.071 mol) in THF (250ml) was cooled on an ice bath. TiCl_3 15% in water (250ml) was added dropwise. The mixture was stirred at room temperature overnight, then poured out into ice water and extracted with DCM. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated till dryness, yielding 20.5g (82.6%) of [2-amino-5(4-methylbenzoyl)phenyl](3-chlorophenyl)-methanone (intermediate 20).
- 15 d) Intermediate 20 (0.0085 mol) was added at 5°C to DCM (30ml) under N_2 flow. trichloro-acetyl chloride (0.01 mol) then triethylamine (0.01mol) were added dropwise. The mixture was brought to room temperature, stirred at room temperature for 3 hours, poured out into ice water and extracted with DCM. The organic layer was separated,
- 20 dried (MgSO_4), filtered, and the solvent was evaporated, yielding 4.2g (quantitative) of 2,2,2-trichloro-*N*-[2-(3-chlorobenzoyl)-4-(4-methylbenzoyl)phenyl]-acetamide (intermediate 21).
- e) A mixture of intermediate 21 (0.0085 mol) and acetic acid, ammonium salt (0.0169 mol) in DMSO (42ml) was stirred at 60°C for 4 hours then cooled and poured out into
- 25 ice water. The precipitate was filtered, washed with water, taken up in warm CH_3CN , filtered off and dried under a vacuo, yielding 2.02g (63%) of 4-(3-chlorophenyl)-6-(4-methylbenzoyl)-2(1*H*)-quinazolinone (intermediate 22), mp. > 260°C.
- f) A mixture of intermediate 22 (0.041 mol) in phosphoryl chloride (105ml) was stirred at 100°C for 4 hours then cooled. The solvent was evaporated. The residue was taken
- 30 up DCM. The solvent was evaporated. The residue was taken up in DCM. The mixture was poured out into ice water, basified with K_2CO_3 10% and extracted. The organic layer was separated, washed with water, dried (MgSO_4), filtered and the solvent was evaporated. The residue was crystallized from CH_3CN . The precipitate was filtered off and dried, yielding 11.4g (70%) of intermediate 23. The mother layer was evaporated
- 35 and purified by column chromatography over silica gel (eluent: cyclohexane/ EtOAc ; 90/10; 15-40 μm). The pure fractions were collected and the solvent was evaporated, yielding 1.7g (10.5%) of [2-chloro-4-(3-chlorophenyl)-6-quinazolinyl](4-methylphenyl)-methanone (intermediate 24), mp. 156°C.

- g) 1-Methyl-1*H*-imidazole (0.0507 mol) was added at -70°C to THF (90ml) under N₂ flow. nBuLi (31.5ml) was added dropwise. The mixture was stirred at -70°C for 15 minutes. Chlorotriethyl-silane (0.0522 mol) was added dropwise. The mixture was stirred at -70°C for 15 minutes. nBuLi (28ml) was added. The mixture was stirred at -70°C for 15 minutes. A mixture of intermediate 23 (0.029 mol) in THF (115ml) was added dropwise. The mixture was stirred at -70°C for 1 hour, poured out into water and extracted with DCM. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH; 96/4/0.1; 15-35μm). The pure fractions were collected and the solvent was evaporated, yielding 9g (65%). A sample (0.3g) was crystallized from 2-propanone. The precipitate was filtered off and dried, yielding 2-chloro-4-(3-chlorophenyl)-α-(1-methyl-1*H*-imidazol-5-yl)-α-(4-methylphenyl)-6-quinazolinemethanol (intermediate 24), mp. 220°C.
- h) A mixture of intermediate 24 (0.0105 mol) and NaN₃ (0.031 mol) in DMF (70ml) was stirred at 90°C for 2 hours then cooled and poured out into ice water. The precipitate was filtered and taken up in DCM. The organic layer was washed with water, separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH; 95/5/0.1; 15-40μm). The pure fractions were collected and the solvent was evaporated, yielding 3.68g (quantitative) of 5-(3-chlorophenyl)-α-(1-methyl-1*H*-imidazol-5-yl)-α-(4-methylphenyl)-tetrazolo[1,5-*a*]quinazoline-7-methanol (intermediate 25), mp. 200°C.
- i) A mixture of intermediate 25 (0.0083 mol) in thionyl chloride (80ml) was stirred at 60°C for 3 hours, then cooled and the solvent was evaporated. The residue was taken up in DCM. The solvent was evaporated, yielding 7-[chloro(1-methyl-1*H*-imidazol-5-yl)(4-methylphenyl)methyl]-5-(3-chlorophenyl)-tetrazolo[1,5-*a*]quinazoline hydrochloride (1:1) (intermediate 26). This product was used directly in the next reaction step.
- j) A mixture of intermediate 26 (0.0083 mol) in THF (80ml) was cooled to 5°C under N₂ flow. NH₃/iPrOH (80ml) was added dropwise. The mixture was stirred at 5°C for 1 hours, then brought to room temperature. The mixture was stirred at room temperature overnight, poured out into ice water and extracted with DCM. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.2; 15-40μm). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from CH₃CN. The precipitate was filtered off and dried, yielding 1.37g (33%) of 5-(3-chlorophenyl)-α-(1-methyl-1*H*-

imidazol-5-yl)- α -(4-methylphenyl)- tetrazolo[1,5-*a*]quinazoline-7-methanamine .hydrate (1:1) (intermediate 27) , mp. 150°C.

k) NaBH₄ (0.0005 mol) was added portionwise at room temperature to a mixture of intermediate 27 (0.0005 mol) in methanol (2.5ml). The mixture was stirred at room temperature for 2 hours and poured out into ice water. DCM was added. The mixture was extracted with DCM. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over kromasil (eluent: CH₂Cl₂/CH₃OH/Et₃N 97/3/0.3; 5 μ m). The pure fractions were collected and the solvent was evaporated. The residue (0.1g, 40%) was taken up in diethyl ether and dried in a vacuo, yielding 0.07g (28%) of 5-(3-chlorophenyl)-4,5-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- α -(4-methylphenyl)-tetrazolo[1,5-*a*]quinazoline-7-methanamine (intermediate 28), mp. 140°C.

B. Preparation of the final compounds

Example B1

A mixture of (\pm)-5-(3-chlorophenyl)- α -(4-chlorophenyl)-4,5-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)tetrazolo[1,5-*a*]quinazoline-7-methanol described in International application WO00/39082 (0.0013 mol) in toluene (15ml) was stirred at 120°C for 6 hours, then cooled to room temperature and the solvent was evaporated till dryness. The residue was crystallized from CH₂Cl₂/CH₃OH/DIPE. The precipitate was filtered off and dried, yielding 0.19g (27%) of 9-(3-chlorophenyl)- α -(4-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- tetrazolo[5,1-*b*]quinazoline-7-methanol (compound 1), mp. >260°C.

Example B2

A mixture of intermediate 9 (0.0014 mol) in toluene (10ml) was stirred and refluxed for 48 hours, then brought to room temperature and the solvent was evaporated till dryness. The residue was taken up in DCM. The solvent was evaporated till dryness. The residue was purified by column chromatography over kromasil (eluent: CH₂Cl₂/CH₃OH/Et₃N 95/5/0.1; 10 μ m). The pure fractions were collected and the solvent was evaporated. The residue (0.4g, 57%) was washed with diethyl ether. The precipitate was filtered off and dried under a vacuo, yielding 0.35g (50%) of 9-(3-chlorophenyl)- α -(4-fluorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)-tetrazolo[5,1-*b*]quinazoline-7-methanol (compound 2), mp. 180°C.

Example B3

A mixture of intermediate 17 (0.0006 mol) in toluene (10ml) was stirred and refluxed for 5 hours. Then brought to room temperature and the solvent was evaporated till

dryness. The residue was taken up in DCM. The solvent was evaporated till dryness. The residue was purified by column chromatography over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{Et}_3\text{N}$ 95/5/0.5; $10\mu\text{m}$). The pure fractions were collected and the solvent was evaporated. The residue (0.12g, 40%) was taken up in DCM. The solvent was evaporated till dryness, yielding 0.08g (27%) of 9-(3-chlorophenyl)-4,9-dihydro- α -(4-methoxyphenyl)- α -(1-methyl-1*H*-imidazol-5-yl)- tetrazolo[5,1-*b*]quinazoline-7-methanol (compound 3).

Example B4

A mixture of intermediate 28 (0.0001 mol) in toluene (1ml) was stirred at 120°C for 6 hours, then brought to room temperature and the solvent was evaporated till dryness. The residue was taken up in DCM. The solvent was evaporated till dryness. The residue was purified by column chromatography over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 96/4; $10\mu\text{m}$). Two fractions were collected and the solvent was evaporated, yielding 0.012g (24%) of 9-(3-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- α -(4-methylphenyl)- tetrazolo[5,1-*b*]quinazoline-7-methanamine (A) (compound 4) and 0.01g (20%) of 9-(3-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- α -(4-methylphenyl)- tetrazolo[5,1-*b*]quinazoline-7-methanamine (B) (compound 5).

C. Pharmacological example.

Example C.1 : "In Vitro Assay for Inhibition of Farnesyl Protein Transferase" :

An in vitro assay for inhibition of farnesyl transferase was performed essentially as described in WO 98/40383, pages 33-34. Herein the effects of test compounds are expressed as pIC_{50} (the negative log value of the IC_{50} -value). 9-(3-Chlorophenyl)- α -(4-fluorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- tetrazolo[5,1-*b*]quinazoline-7-methanol was found to have a pIC_{50} of 8.75, 9-(3-chlorophenyl)-4,9-dihydro- α -(4-methoxyphenyl)- α -(1-methyl-1*H*-imidazol-5-yl)- tetrazolo[5,1-*b*]quinazoline-7-methanol had a pIC_{50} of 7.63, 9-(3-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- α -(4-methylphenyl)- tetrazolo[5,1-*b*]quinazoline-7-methanamine (A) had a pIC_{50} of 7.46 and 9-(3-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- α -(4-methylphenyl)- tetrazolo[5,1-*b*]quinazoline-7-methanamine (B) had a $\text{pIC}_{50} > 9$.

Example C.2 : "Ras-Transformed Cell Phenotype Reversion Assay".

The *ras*-transformed cell phenotype reversion assay can be performed essentially as described in WO 98/40383, pages 34-36.

D. Composition example : Film-coated tablets

Preparation of tablet core

5 A mixture of 100 g of a compound of formula (I), 570 g lactose and 200 g starch is mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinyl-pyrrolidone in about 200 ml of water. The wet powder mixture is sieved, dried and sieved again. Then there are added 100 g microcrystalline cellulose and 15 g hydrogenated vegetable oil. The whole is mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of a compound of formula (I).

10 Coating

To a solution of 10 g methyl cellulose in 75 ml of denaturated ethanol there is added a solution of 5 g of ethyl cellulose in 150 ml of dichloromethane. Then there are added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol 10 g of polyethylene glycol is molten and dissolved in 75 ml of dichloromethane. The latter solution is added to the
15 former and then there are added 2.5 g of magnesium octadecanoate, 5 g of polyvinyl-pyrrolidone and 30 ml of concentrated colour suspension and the whole is homogenated. The tablet cores are coated with the thus obtained mixture in a coating apparatus.

20


Claims

EPO - DG 1

15.04.2007

(102)

1. A compound of formula (I):



or a pharmaceutically acceptable salt or N-oxide or stereochemically isomeric form thereof, wherein

r and s are each independently 0, 1, 2 or 3;

t is 0, 1, or 2;


each R^1 and R^2 are independently hydroxy, halo, cyano, nitro, C_{1-6} alkyl, $-(CR^{16}R^{17})_p$, $-C_{3-10}$ cycloalkyl, cyano C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, hydroxycarbonyl C_{1-6} alkyl, $R^{20}SC_{1-6}$ alkyl, trihalomethyl, aryl C_{1-6} alkyl, Het^1C_{1-6} alkyl, $-C_{1-6}$ alkyl- $NR^{18}R^{19}$, $-C_{1-6}$ alkyl- $NR^{18}C_{1-6}$ alkyl- $NR^{18}R^{19}$, $-C_{1-6}$ alkyl- $NR^{18}COC_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $NR^{18}COAlkAr^1$, $-C_{1-6}$ alkyl- $NR^{18}COAr^1$, C_{1-6} alkylsulphonylamino C_{1-6} alkyl, C_{1-6} alkyloxy, hydroxy C_{1-6} alkyloxy, C_{1-6} alkyloxy C_{1-6} alkyloxy, $-OC_{1-6}$ alkyl- $NR^{18}R^{19}$, trihalomethoxy, aryl C_{1-6} alkyloxy, Het^1C_{1-6} alkyloxy, C_{2-6} alkenyl, cyano C_{2-6} alkenyl, $-C_{2-6}$ alkenyl- $NR^{18}R^{19}$, hydroxycarbonyl C_{2-6} alkenyl, C_{1-6} alkyloxycarbonyl C_{2-6} alkenyl, C_{2-6} alkynyl, $-CHO$, C_{1-6} alkylcarbonyl, hydroxy C_{1-6} alkylcarbonyl, hydroxycarbonyl, C_{1-6} alkyloxycarbonyl, $-CONR^{18}R^{19}$, $-CONR^{18}-C_{1-6}$ alkyl- $NR^{18}R^{19}$, $-CONR^{18}-C_{1-6}$ alkyl- Het^1 , $-CONR^{18}-C_{1-6}$ alkyl- Ar^1 , $-CONR^{18}-O-C_{1-6}$ alkyl, $-CONR^{18}-C_{1-6}$ alkenyl, $-NR^{18}R^{19}$, $-OC(O)R^{20}$, $-CR^{20}=NR^{21}$, $-CR^{20}=N-OR^{21}$, $-NR^{20}C(O)NR^{18}R^{19}$, $-NR^{20}SO_2R^{21}$, $-NR^{20}C(O)R^{21}$, $-S(O)_{0-2}R^{20}$, $-SO_2NR^{20}R^{21}$, $-C(NR^{22}R^{23})=NR^{24}$, or a group of formula



in which R^y is hydrogen or C_{1-4} alkyl and Z is phenyl or a 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, sulphur and nitrogen, the phenyl or heterocyclic ring being optionally substituted by one or two substituents each

independently selected from halo, cyano, hydroxycarbonyl, aminocarbonyl, C₁₋₆alkylthio, hydroxy, -NR¹⁸R¹⁹, C₁₋₆alkylsulphonylamino, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkyloxy or phenyl; or

5 two R¹ and R² substituents adjacent to one another on the phenyl ring may independently form together a bivalent radical of formula



R¹⁶ and R¹⁷ are independently hydrogen or C₁₋₆ alkyl and are independently defined for each iteration of p in excess of 1;

15 R¹⁸ and R¹⁹ are independently hydrogen, C₁₋₆ alkyl or -(CR¹⁶R¹⁷)_p -C₃₋₁₀cycloalkyl, or together with the adjacent nitrogen atom form a 5- or 6-membered heterocyclic ring optionally containing one, two or three further heteroatoms selected from oxygen, nitrogen or sulphur and optionally substituted by one or two substituents each independently selected from halo,

20 hydroxy, cyano, nitro, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkyloxy, OCF₃, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, aminocarbonyl, mono- or di-(C₁₋₆alkyl)aminocarbonyl, amino, mono- or di-(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonylamino, oxime, or phenyl;

R²⁰ and R²¹ are independently hydrogen, C₁₋₆alkyl,

25 -(CR²⁰R²¹)_p-C₃₋₁₀cycloalkyl or arylC₁₋₆alkyl;

R²², R²³ and R²⁴ are independently hydrogen and C₁₋₆alkyl or C(O) C₁₋₆alkyl;

R³ is hydrogen, halo, cyano, C₁₋₆alkyl, -(CR¹⁶R¹⁷)_p -C₃₋₁₀cycloalkyl, haloC₁₋₆alkyl, cyanoC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, arylC₁₋₆alkyloxy C₁₋₆alkyl, C₁₋₆alkylthioC₁₋₆alkyl, hydroxycarbonylC₁₋₆alkyl, C₁₋₆alkylcarbonyl C₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, -C₁₋₆alkyl-NR¹⁸R¹⁹, -C₁₋₆alkyl-CONR¹⁸R¹⁹, arylC₁₋₆alkyl, Het¹C₁₋₆alkyl, C₂₋₆alkenyl, -C₂₋₆alkenyl NR¹⁸R¹⁹, C₂₋₆alkynyl, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, aryl, or Het¹; or

35 a radical of formula





(b-3) or



(b-4)

wherein R^7 is hydrogen, C_{1-6} alkyl, $-(\text{CR}^{16}\text{R}^{17})_p-\text{C}_{3-10}$ cycloalkyl, aryl C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkylcarbonyl or $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{OC}_{1-6}$ alkyl $\text{NR}^{18}\text{R}^{19}$, or a radical of formula $-\text{Alk}-\text{OR}^{10}$ or $-\text{Alk}-\text{NR}^{11}\text{R}^{12}$;

R^8 is hydrogen, C_{1-6} alkyl, $-(\text{CR}^{16}\text{R}^{17})_p-\text{C}_{3-10}$ cycloalkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

R^9 is hydrogen, hydroxy, C_{1-6} alkyl, $-(\text{CR}^{16}\text{R}^{17})_p-\text{C}_{3-10}$ cycloalkyl, C_{1-6} alkylcarbonyl C_{1-6} alkyl, aryl C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, C_{1-6} alkyloxy, a group of formula $-\text{NR}^{18}\text{R}^{19}$, C_{1-6} alkylcarbonylamino, C_{1-6} alkylcarbonyl, halo C_{1-6} alkylcarbonyl, aryl C_{1-6} alkylcarbonyl, arylcarbonyl, C_{1-6} alkyloxycarbonyl, trihalo C_{1-6} alkyloxycarbonyl, C_{1-6} alkyloxy C_{1-6} alkylcarbonyl, aminocarbonyl, mono- or di(C_{1-6} alkyl)aminocarbonyl wherein the alkyl moiety may optionally be substituted by one or more substituents independently selected from aryl and C_{1-6} alkyloxycarbonyl substituents; aminocarbonylcarbonyl, mono- or di(C_{1-6} alkyl)amino C_{1-6} alkylcarbonyl, or a radical of formula $-\text{Alk}-\text{OR}^{10}$ or $\text{Alk}-\text{NR}^{11}\text{R}^{12}$;


wherein Alk is C_{1-6} alkanediyl;

R^{10} is hydrogen, C_{1-6} alkyl, $-(\text{CR}^{16}\text{R}^{17})_p-\text{C}_{3-10}$ cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkylcarbonyl or hydroxy C_{1-6} alkyl;

R^{11} is hydrogen, C_{1-6} alkyl, $-(\text{CR}^{16}\text{R}^{17})_p-\text{C}_{3-10}$ cycloalkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;


R^{12} is hydrogen, C_{1-6} alkyl, $-(\text{CR}^{16}\text{R}^{17})_p-\text{C}_{3-10}$ cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-6} alkylcarbonyl;

R^4 is a radical of formula



(c-1)

or



(c-2)

wherein R^{13} is hydrogen, halo or C_{1-6} alkyl;

R^{14} is hydrogen or C_{1-6} alkyl;

R^{15} is hydrogen or C_{1-6} alkyl;

R^5 is cyano, hydroxy, halo, C_{1-6} alkyl, $-(CR^{16}R^{17})_p$ $-C_{3-10}$ cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkyloxy, hydroxycarbonyl, C_{1-6} alkyloxycarbonyl, or a group of formula $-NR^{18}R^{19}$ or $-CONR^{18}R^{19}$;

- 5 R^6 is hydrogen, C_{1-6} alkyl, $-(CR^{16}R^{17})_p$ $-C_{3-10}$ cycloalkyl, cyano C_{1-6} alkyl, $-C_{1-6}$ alkyl CO_2R^{20} , aminocarbonyl C_{1-6} alkyl or $-C_{1-6}$ alkyl- $NR^{18}R^{19}$, $R^{20}SO_2$, $R^{20}SO_2C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- OR^{20} , $-C_{1-6}$ alkyl- SR^{20} , $-C_{1-6}$ alkyl $CONR^{18}$ - C_{1-6} alkyl- $NR^{18}R^{19}$, $-C_{1-6}$ alkyl $CONR^{18}$ - C_{1-6} alkyl-Het¹, $-C_{1-6}$ alkyl $CONR^{18}$ - C_{1-6} alkyl-Ar¹, $-C_{1-6}$ alkyl $CONR^{18}$ -Het¹,
10 $-C_{1-6}$ alkyl $CONR^{18}$ Ar¹, $-C_{1-6}$ alkyl $CONR^{18}$ -O- C_{1-6} alkyl, $-C_{1-6}$ alkyl $CONR^{18}$ - C_{1-6} alkenyl, -Alk-Ar¹ or -AlkHet¹;

Ar¹ is phenyl, naphthyl or phenyl or naphthyl substituted by one to five substituents each independently selected from halo, hydroxy, cyano, nitro, C_{1-6} alkyl, halo C_{1-6} alkyl, -alkyl $NR^{18}R^{19}$, C_{1-6} alkyloxy, OCF_3 , hydroxycarbonyl, C_{1-6} alkyloxycarbonyl, $-CONR^{18}R^{19}$, $-NR^{18}R^{19}$, C_{1-6} alkylsulfonylamino, oxime or phenyl, or a bivalent substituent of formula



- 20 Het¹ is a mono- or bi-cyclic heterocyclic ring containing one or more heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by one or two substituents each independently selected from halo, hydroxy, cyano, nitro, C_{1-6} alkyl, halo C_{1-6} alkyl, -alkyl $NR^{18}R^{19}$, $-C_{1-6}$ alkyloxy, OCF_3 , hydroxycarbonyl, C_{1-6} alkyloxycarbonyl;
25 $-CONR^{18}R^{19}$, $-NR^{18}R^{19}$, C_{1-6} alkylsulfonylamino, oxime or phenyl:

2. A compound according to claim 1 wherein R^1 is halo; R^2 is halo, C_{1-6} alkyl or C_{1-6} alkyloxy; R^3 is a radical of formula (b-1) or (b-3) wherein R^7 is hydrogen, R^8 is hydrogen and R^9 is hydrogen; R^4 is a radical of formula (c-1) wherein R^{13} is hydrogen and R^{14} is C_{1-6} alkyl; and R^6 is hydrogen.

30

3. A compound according to claim 1 and 2 selected from:

9-(3-chlorophenyl)- α -(4-fluorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- tetrazolo[5,1-*b*]quinazoline-7-methanol

9-(3-chlorophenyl)-4,9-dihydro- α -(4-methoxyphenyl)- α -(1-methyl-1*H*-imidazol-5-yl)- tetrazolo[5,1-*b*]quinazoline-7-methanol

5

9-(3-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- α -(4-methylphenyl)- tetrazolo[5,1-*b*]quinazoline-7-methanamine (A)

9-(3-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- α -(4-methylphenyl)- tetrazolo[5,1-*b*]quinazoline-7-methanamine (B)

10

9-(3-chlorophenyl)- α -(4-chlorophenyl)-4,9-dihydro- α -(1-methyl-1*H*-imidazol-5-yl)- tetrazolo[5,1-*b*]quinazoline-7-methanol

15

4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as described in any one of claims 1 to 3.

20

5. A process for preparing a pharmaceutical composition as claimed in claim 4 wherein a therapeutically effective amount of a compound as claimed in any one of claims 1 to 3 is intimately mixed with a pharmaceutically acceptable carrier.

25

6. A compound according to any of claims 1 to 3 for use as a medicine.


7. The use of a compound according to claim 1 to 3 in the manufacture of a medicament for inhibiting tumor growth.

8. The use of a compound according to claim 1 to 3 in the manufacture of a medicament to treat proliferative disorders.


30

9. A process for the preparation of a compound as claimed in claim 1 which comprises:


a) Converting intermediates of formula (V) in compounds of formula (I) wherein R⁶ is hydrogen said compounds being referred to as compounds of formula (I-g) by heating at 120 °C in an appropriate solvent; and




5 b) reacting an intermediate ketone of formula (II) with an intermediate imidazole of formula (III-a-1) wherein R^{14} is C_{1-6} alkyl with the formation of compounds of formula (I) wherein R^4 represents a radical of formula (c-1), R^3 is hydroxy and R^{14} is C_{1-6} alkyl, said compounds being referred to as compounds of formula (I-a-1); and




10 c) reacting an intermediate ketone of formula (II) with an intermediate imidazole reagent of formula (III-b-1) wherein P is an optional protective group and R^{14} is hydrogen and subsequently removal of P with the formation of a compound of formula (I) wherein R^4 is a radical of formula (c-1), R^3 is hydroxy and R^{14} is hydrogen said compound being referred to as compounds of formula (I-b-1); and



d) removing the $-S-R^{25}$ group, wherein R^{25} is hydrogen or C_{1-6} alkyl from the intermediate of formulae (IVa-2) wherein R^4 is a radical of formula (c-2), R^{15} is C_{1-6} alkyl and R^3 is hydroxy with the formation of compounds of formula (I), wherein R^4 is a radical of formula (c-2), R^{15} is C_{1-6} alkyl and R^3 is hydroxy, said compounds being referred to as compounds of formula (I-a-2); and



e) reacting an intermediate ketone of formula (II) with an intermediate triazole reagent of formula (III-b-2) wherein P is an optional protective group and subsequently removal of P with the formation of a compound of formula (I) wherein R⁴ is a radical of formula (c-2), R³ is hydroxy and R¹⁴ is hydrogen said compound being referred to as compounds of formula (I-b-2) ; and




f) optionally effecting one or more of the following conversions in any desired order:

- 5 (i) converting a compound of formula (I) into a different compound of formula (I);
- (ii) converting a compound of formula (I) into a pharmaceutically acceptable salt or N-oxide thereof;
- 10 (iii) converting a pharmaceutically acceptable salt or N-oxide of a compound of formula (I) into the parent compound of formula (I);
- (iv) preparing a stereochemical isomeric form of a compound of formula (I) or a pharmaceutically acceptable salt or N-oxide thereof.

ABSTRACT

FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE
DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR
TRIAZOLES

This invention comprises the novel compounds of formula (I)



wherein r , s , t , R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 have defined meanings, having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.

EPO - DG 1

15.04.2000

(102)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.